19 September 2017 - - US-based medical technology company BD (Becton, Dickinson and company) (NYSE: BDX) has launched the BD Ultra-Fine micro pen needle 6mm x 32G for use with leading pen injection devices, that is set for distribution starting September 2017, the company said.

With this launch, BD is providing health care practitioners with an additional needle length option manufactured with BD quality and reliability to provide a wider range of needle lengths for people with diabetes who inject insulin.

The introduction of the new pen needle rounds out the BD Ultra-Fine pen needle portfolio, which now includes 4mm x 32G, 5mm x 31G, 6mm x 32G, 8mm x 31G and 12.7mm x 29G.

BD Ultra-Fine micro 6mm pen needles are covered at the preferred co-pay by most insurance plans including Medicare part D and are compatible with leading pen injection devices.

People with diabetes typically inject insulin one or more times per day into the subcutaneous fat of their abdomen, thigh, upper arm or buttocks.

With shorter needles, including BD Ultra-Fine micro pen needles, people with diabetes are less likely to accidentally inject their insulin dose into a muscle.

The BD Ultra-Fine pen needles are designed for a comfortable injection experience, supporting customer satisfaction and loyalty. This includes electro-polished, surgical grade needles designed for smoothness and proprietary micro-bonded needle lubrication for less friction. All BD Ultra-Fine pen needles are designed to deliver a full accurate dose.

BD is a global medical technology company that is advancing the world of health by improving medical discovery, diagnostics and the delivery of care.

The company provides solutions for medical research and genomics, to enhance the diagnosis of infectious disease and cancer, improve medication management, promote infection prevention, equip surgical and interventional procedures, and support the management of diabetes.